Daiichi Sankyo Shares Gain After Prasugrel Drug Study (Japan)
This article was originally published in PharmAsia News
Promising results from a large, late-stage clinical trial sent Daiichi Sankyo's share's skyrocketing 7.4 percent Monday, the company's biggest single gain since it went public on the Tokyo Stock Exchange in 2005. A late-stage study of 13,608 patients found prasugrel was more effective than market leader Plavix in preventing heart attacks. Results presented at the American Heart Association's yearly meeting showed only 9.9 percent of patients who took prasugrel suffered major cardiovascular events during the trial, compared to 12 percent of those on Plavix. The study, sponsored by Daiichi and co-developer Eli Lilly, also showed prasugrel was faster acting than Plavix. Recently, Daiichi and Lily halted two prasugrel trials, citing a need for dosing changes. The announcement made many insiders worry there might be serious risks associated with the drug. Although prasugrel did show a higher bleeding risk than Plavix, researchers say it should not be enough to prevent regulatory approval. (Click here for more - May Require Free Registration
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.